Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Dose Escalation and Dose Expansion, First-in-human, Open-Labeled Study of ETH-155008 in Subjects With Relapsed or Refractory B-cell NHL, CLL/SLL and AML

NCT04840784 is registered in ClinicalTrials.gov with Shengke Pharmaceuticals Pty Ltd as lead sponsor.

NCT NCT04840784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04840784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Dose Escalation and Dose Expansion, First-in-human, Open-Labeled Study of ETH-155008 in Subjects With Relapsed or Refractory B-cell NHL, CLL/SLL and AML
Lead sponsor
Shengke Pharmaceuticals Pty Ltd
Phase
Phase 1
Overall status
Terminated
Start date
June 29, 2021
Completion date
May 2, 2023
Enrollment
9 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, nhl